Search results
Showing 451 to 465 of 735 results for adult social
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.
Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)
Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults.
Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.
Our forward view highlights the topics we will prioritise in the coming year.
This quality standard covers assessment, early management and rehabilitation following head injury in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS74Show all sections
Sections for QS74
- Quality statements
- Quality statement 1: CT head scans
- Quality statement 2: CT head scans for people taking anticoagulants
- Quality statement 3: CT cervical spine scans
- Quality statement 4: Provisional radiology reports
- Quality statement 5: Access to neuroscience units
- Quality statement 6: Inpatient rehabilitation for people with traumatic brain injury
- Quality statement 7: Community rehabilitation services for people with traumatic brain injury
This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS52Show all sections
Sections for QS52
- Quality statements
- Quality statement 1: Identification and assessment of peripheral arterial disease
- Quality statement 2: Comorbidity assessment
- Quality statement 3: Supervised exercise programmes
- Quality statement 4: Imaging
- Quality statement 5: Angioplasty for intermittent claudication
- About this quality standard
This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.
NICE has developed a Medtech Innovation Briefing (MIB) on the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive care
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)
Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.
Regorafenib for previously treated metastatic colorectal cancer (TA866)
Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on the needle-free arterial non-injectable connector .
Evidence-based recommendations on azacitidine (Onureg) for maintenance treatment of acute myeloid leukaemia after induction therapy in adults.
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)
Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.